FDA Approval Sought for Rituximab Biosimilar
A biologics license application has been submitted to the FDA for the rituximab biosimilar ABP 798.
Related Articles
First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.
Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care
R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.
Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm
Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.
Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer
Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification
Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.
Common Medication for Lung Cancer Symptoms Found to Limit Effectiveness of Cancer Treatment
High doses of corticosteroids are likely the most significant factor in why some immunotherapies don’t work.
New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies
In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.